prikaz prve stranice dokumenta Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
Rad dostupan nakon 2025-01-01
Znanstveni rad - Izvorni znanstveni rad
Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
Expert Opinion on Drug Safety, 22 (2023), 12; 1265-1270. https://doi.org/10.1080/14740338.2023.2234821
Lucijanić, Marko; Bušić, Nikolina; Stojić, Josip; Barišić-Jaman, Mislav; Zagorec, Nikola; Lazibat, Karla; Pasarić, Antica; Vrkljan Vuk, Anamarija; Durlen, Ivan; Mitrović, Joško; Lukšić, Ivica; Baršić, Bruno

Citirajte ovaj rad

Lucijanić, M., Bušić, N., Stojić, J., Barišić Jaman, M., Zagorec, N., Lazibat, K. ... Baršić, B. (2023). Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety, 22. (12), 1265-1270. doi: 10.1080/14740338.2023.2234821

Lucijanić, Marko, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety, vol. 22, br. 12, 2023, str. 1265-1270. https://doi.org/10.1080/14740338.2023.2234821

Lucijanić, Marko, Nikolina Bušić, Josip Stojić, Mislav Barišić Jaman, Nikola Zagorec, Karla Lazibat, Antica Pasarić, et al. "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate." Expert Opinion on Drug Safety 22, br. 12 (2023): 1265-1270. https://doi.org/10.1080/14740338.2023.2234821

Lucijanić, M., et al. (2023) 'Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate', Expert Opinion on Drug Safety, 22(12), str. 1265-1270. doi: 10.1080/14740338.2023.2234821

Lucijanić M, Bušić N, Stojić J, Barišić Jaman M, Zagorec N, Lazibat K, i sur.. Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate. Expert Opinion on Drug Safety [Internet]. 10.07.2023. [pristupljeno 19.12.2024.];22(12):1265-1270. doi: 10.1080/14740338.2023.2234821

M. Lucijanić, et al., "Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate", Expert Opinion on Drug Safety, vol. 22, br. 12, str. 1265-1270, Srpanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:861487. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:861487
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Proton pump inhibitors use prior to COVID-19 hospitalization is associated with higher C lostridioides difficile infection rate
AutorMarko Lucijanić
AutorNikolina Bušić
AutorJosip Stojić
AutorMislav Barišić-Jaman
AutorNikola Zagorec
AutorKarla Lazibat
AutorAntica Pasarić
AutorAnamarija Vrkljan Vuk
AutorIvan Durlen
AutorJoško Mitrović
AutorIvica Lukšić
AutorBruno Baršić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MAKSILOFACIJALNU KIRURGIJU SA STOMATOLOGIJOM)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Kirurgija
Sažetak (engleski)
Background: There are uncertainties regarding associations of prior proton pump inhibitor (PPI) use with susceptibility for COVID-19 and risks associated with SARS-CoV-2 infection. We aimed to evaluate the associations of prior PPI use with outcomes in hospitalized patients with COVID-19. Research design and methods: We have retrospectively evaluated a total of 5959 consecutively hospitalized patients with COVID-19 from a tertiary-level institution in the period 3/2020-6/2021. Associations of prior PPI use with outcomes of in-hospital mortality, mechanical ventilation, intensive care unit stay, venous thromboembolism, arterial thrombosis, major bleeding, bacteremia, and Clostridioides difficile infection (C. diff.) were evaluated in entire and case-matched cohorts. Results: Among 5959 evaluated patients, there were 1967 (33%) PPI users. In an entire cohort, prior PPI use was associated with higher in-hospital mortality and higher occurrence of C. diff. Association of prior PPI use with mortality diminished, whereas association with C. diff. persisted after multivariable adjustments. In a matched cohort, prior PPI use was associated only with higher risk of C. diff. but not other outcomes in line with multivariable analysis. Conclusions: Although prior PPI use might not have a significant impact on clinical course and mortality of SARS-CoV-2 infection, it may predispose patients to the development of complications like higher occurrence of C. diff. and thus substantially impact the course of treatment.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaExpert Opinion on Drug Safety
Brojčani podacivol. 22, br. 12, str. 1265-1270
p-ISSN1474-0338
e-ISSN1744-764X
DOIhttps://doi.org/10.1080/14740338.2023.2234821
URN:NBNurn:nbn:hr:105:861487
Datum objave publikacije2023-07-10
URL dokumentahttps://www.tandfonline.com/doi/full/10.1080/14740338.2023.2234821
Vrsta resursaTekst
Prava pristupaPristup ograničen embargom
Datum isteka embarga: 2025-01-01
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-10-21 10:34:08